Idor­sia sells off Asian op­er­a­tions, top drug li­cens­es to So­sei Hep­tares in $465M deal

Swiss bio­phar­ma Idor­sia has sold off a large part of its op­er­a­tions in the Asia Pa­cif­ic to So­sei Hep­tares for $465.8 mil­lion (400 mil­lion CHF), the com­pa­nies an­nounced Thurs­day.

The agree­ment cov­ers Idor­sia’s af­fil­i­ates in Japan and South Ko­rea, as well as rights to Idor­sia drugs — in­clud­ing a li­cense for the cere­bral va­sospasm drug Pivlaz, a co-ex­clu­sive li­cense for the in­som­nia drug dari­dorex­ant (sold in the US and Eu­rope as Qu­viviq), as well as the pos­si­bil­i­ty for So­sei Hep­tares to li­cense, de­vel­op and com­mer­cial­ize two more drugs, cene­r­i­mod and lucera­s­tat. Idor­sia will sup­ply Pivlaz and dari­dorex­ant in bulk to So­sei. The deal ex­cludes Chi­na.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER